Trial Profile
Double blind, parallel-group clinical study of AD-810N (zonisamide) for Parkinson's disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Zonisamide (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 15 Nov 2021 Results of post-hoc pooled analysis of two studies (JapicCTI-050099 [phase 2b/3] and JapicCTI-101198 [phase 3])) published in the Journal of the Neurological Sciences.
- 14 Jun 2016 New trial record